Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-Like Cells

• Main Authors: Brandner, S. (Author), Ernestus, R.-I (Author), Feldheim, J. (Author), Feldheim, J.J (Author), Glas, M. (Author), Hagemann, C. (Author), Kessler, A.F (Author), Kleinschnitz, C. (Author), Lazaridis, L. (Author), Löhr, M. (Author), Monoranu, C.M (Author), Schulz, E. (Author), Wend, D. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: astrocytoma; cancer stem cells; glioblastoma; IDH; MGMT; temozolomide; therapy
• Online Access: View Fulltext in Publisher

 Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). The MGMT promoter methylation, the main regulator of MGMT expression, can change from primary tumor to recurrence, and TMZ may play a significant role in this process. To identify the potential mechanisms involved, three primary stem-like cell lines (one astrocytoma with the mutation of the isocitrate dehydrogenase (IDH), CNS WHO grade 4 (HGA)), and two glioblastoma (IDH-wildtype, CNS WHO grade 4) were treated with TMZ. The MGMT promoter methylation, migration, proliferation, and TMZ-response of the tumor cells were examined at different time points. The strong effects of TMZ treatment on the MGMT methylated cells were observed. Furthermore, TMZ led to a loss of the MGMT promoter hypermethylation and induced migratory rather than proliferative behavior. Cells with the unmethylated MGMT promoter showed more aggressive behavior after treatment, while HGA cells reacted heterogenously. Our study provides further evidence to consider the potential adverse effects of TMZ chemotherapy and a rationale for investigating potential relationships between TMZ treatment and change in the MGMT promoter methylation during relapse. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.